{
    "symbol": "EXAS",
    "quarter": 4,
    "year": 2022,
    "date": "2023-02-21 21:07:04",
    "content": " Achievements in 2022 that helped strengthen our leadership include surpassing 12 million cumulative people tested for cancer, including 10 million with colder expanding our global network of ordering healthcare professionals to more than 350,000, growing core revenue $380 million year-over-year, becoming adjusted EBITDA profitable in the fourth quarter, completing enrollment of BLUE-C, our pivotal study to support our next-generation Cologuard and colon cancer blood tests, and generating evidence for our multi-cancer early detection and molecular residual disease tests. Your line is open. Your line is open. Your line is open. Your line is open. Your line is open. Your line is open. Your line is open. Your line is open. Your line is open. Your line is open. Your line is open. In terms of the ceiling, we think that the ceiling is higher than the 40% penetration that we have long guided to for Cologuard in that earlier age group because people who are 45-year-old to 49-year-old typically are busier than retirees, and it\u00e2\u0080\u0099s more of a challenge for them to schedule a screening colonoscopy, which can take 1.5 days of your life. Your line is open. Your line is open. Your line is open."
}